Get the Daily Brief
Latest Biotech News
Bio-Thera's Stelara Biosimilar Receives European Commission Approval
Bio-Thera Solutions secured European Commission marketing authorization for Usymro (BAT-2206), a biosimilar to Janssen’s Stelara (ustekinumab). The EMA's positive opinion and subsequent approval...
Novartis Doubles Down on RNAi Parkinson’s Therapy with $2.2B Arrowhead Deal
Novartis has secured an exclusive licensing and collaboration agreement with Arrowhead Pharmaceuticals worth up to $2.2 billion, advancing Arrowhead’s RNA interference (RNAi) drug ARO-SNCA...
Ionis’ Tryngolza Clears Major Phase III Trials for Severe Hypertriglyceridemia
Ionis Pharmaceuticals’ antisense oligonucleotide drug, olezarsen (Tryngolza), demonstrated robust efficacy and safety in pivotal Phase III CORE and CORE2 trials for severe hypertriglyceridemia....
United Therapeutics’ Tyvaso Surprises with Phase III Idiopathic Pulmonary Fibrosis Win
United Therapeutics Corp. unveiled unexpectedly positive Phase III data for its nebulized treprostinil product, Tyvaso, in idiopathic pulmonary fibrosis (IPF), a notoriously difficult-to-treat...
Corsera Health Launches with $50M to Transform Cardiovascular Disease Prevention
Biotech veterans John Maraganore and Clive Meanwell have teamed to launch Corsera Health, backed by a $50 million initial funding round, focusing on prevention of cardiovascular disease through...
FDA Approvals and Regulatory Moves Shake Up US Biotech Landscape
The US Food and Drug Administration has recently cleared several significant approvals impacting biotech and healthcare. Highlights include FDA clearance of Geneseeq Technology’s GeneseeqPrime NGS...
Charm Therapeutics Raises $80M to Advance AI-Designed Menin Inhibitor into Clinic
Charm Therapeutics, a London-based biotech co-founded by Nobel laureate David Baker, completed an oversubscribed $80 million Series B to propel its AI-designed menin inhibitor into clinical...
Machine Learning and AI Drive Breakthroughs in Medical Diagnostics and Drug Design
Artificial intelligence and machine learning technologies have made significant inroads across medical diagnostics and therapeutic development. Notable achievements include the development of...
Revvity Opens In Vivo Imaging Center of Excellence to Accelerate Life Science Innovation
Revvity Inc. inaugurated its In Vivo Imaging Center of Excellence in Morrisville, North Carolina, consolidating expertise across software, hardware, and applied biology teams to accelerate...
Merck Advances Oral PCSK9 Program with Third Phase 3 Trial Success
Merck & Co. has achieved a third consecutive Phase 3 trial win for its oral PCSK9 inhibitor in hyperlipidemia, reinforcing its push towards broader regulatory discussions and market expansion. The...
Advances in Cancer Immunotherapy and Targeted Treatments Show Promise Across Cancers
Recent studies highlight progress in cancer immunotherapies and targeted therapies. UCSF researchers have developed a STAT3-targeted oligonucleotide showing efficacy in feline oral tumors,...
Novartis Renewed Bet on RNAi in Parkinson’s: $200M Upfront Arrowhead Deal
Novartis has renewed its pursuit of Parkinson’s disease treatments by licensing a preclinical RNA interference therapy from Arrowhead Pharmaceuticals, centered on silencing the alpha-synuclein...
Ionis’ Olezarsen Triumphs in Severe Hypertriglyceridemia: Phase 3 Wins Spur Expansion
Ionis Pharmaceuticals reported positive pivotal Phase 3 data demonstrating that its antisense oligonucleotide Olezarsen sharply reduces triglyceride levels by up to 72% and cuts acute pancreatitis...
United Therapeutics’ Tyvaso Shakes Up IPF Market With Unexpected Phase 3 Win
United Therapeutics revealed unexpected positive Phase 3 results for nebulized Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF), meeting primary and key secondary endpoints including...
Advanced AI Models Revolutionize Disease Prediction and Diagnostics
Recent advancements in artificial intelligence have introduced powerful tools transforming medical diagnostics. Mount Sinai researchers developed a Graph Neural Network model to guide...
Alzheimer’s Advances: Home Injectable, Gender-Specific Protection, and Brain Network Insights
Innovations in Alzheimer’s disease therapy and understanding are mounting. The FDA recently approved injectable Leqembi by Eisai and Biogen facilitating home-based weekly maintenance dosing,...
Bioinformatics and Genomics Integration: Acquisitions and Collaborations Accelerate Precision Medicine
In a strategic consolidation of genomic analysis, French firm SeqOne acquired UK-based Congenica to merge AI-powered sequencing analysis with clinical decision support. Separately, Golden Helix...
Polymer and Material Science Breakthroughs Propel Medical and Environmental Innovation
Material science advancements continue to impact biotechnology and environment sectors. Kaunas University of Technology developed sustainable, self-healing, antimicrobial vitrimers for...
Breakthroughs in Cancer Immunotherapy and Targeted Therapies
Recent studies underscore innovative advances in cancer treatment modalities. UCSF researchers developed a STAT3-targeting decoy oligonucleotide showing tumor reduction in feline oral cancer,...
Diabetes Management Advances: Oral GLP-1s, Gene Editing, and Continuous Monitoring
Diabetes treatment is evolving rapidly with multiple breakthroughs. Eli Lilly’s orforglipron demonstrated robust weight and A1C reductions in Phase III trials, positioning it as a strong oral...